Business Wire

ATNI

1.7.2021 09:02:13 CEST | Business Wire | Press release

Share
Global Access to Nutrition Index 2021 Calls for Food Industry to Urgently Address Nutrition Gap in the COVID-19 Era

Access to Nutrition Initiative (ATNI) has launched its 2021 Global Index, assessing the world’s 25 largest global food and beverage manufacturers and their contributions to addressing malnutrition. While some companies have shown significant progress since it’s last iteration in 2018, progress from the top 10 ranking manufacturers has slowed. ATNI is urgently calling on companies to step up efforts to tackle some of the world’s toughest nutrition challenges.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210701005100/en/

Malnutrition in any form affects every county in the world, contributing towards millions of deaths and people at risk of diet related diseases. In 2019, 690 million people (8.9% of the global population) were considered undernourished, and with the economic effects of COVID-19 we’re seeing even more people experiencing extreme poverty and the consequences of overweight and diet-related diseases.

FCDO Minister for the European Neighbourhood and the Americas, Wendy Morton said: “We welcome the launch of this year’s Index, particularly as COVID-19 has worsened levels of malnutrition and the availability of food globally. We have a unique opportunity to address this in ways that benefit everyone. We must hold the world’s biggest food and beverage companies to account to help speed up our global recovery from the pandemic.”

Inge Kauer, Executive Director of ATNI, added, As the 25 largest food and beverage manufacturers, each must take responsibility to deliver healthy product offerings to consumers across the globe and not leave nutrition behind. That’s no small task – but it’s one that requires action urgently if we are to deliver on the Sustainable Development Goals to end world hunger and ensure good health and well-being.”

Highlights and Rankings

All companies were assessed on their commitments, practices, and disclosure – with regards to governance and management, the production and distribution of healthy, affordable, accessible products, and how companies influence consumer choices and behavior.

  • The average score remained the same as 2018: 3.3/10.
    • Nestlé led the 2021 ranking with a score of 6.7. The company achieved a top-3 rank in all categories and ranked first on ‘Governance’, and ‘Engagement’.
    • Unilever came second with 6.3, and FrieslandCampina third with 5.9.
    • Arla showed a big improvement from 3.3 in 2018 to 5.1 in 2021, largely because of a new labeling policy, responsible marketing policies, and an improvement in healthiness of its product portfolio.
    • Meiji rose four places, partially due to incorporation of a nutrition strategy in its CSR vision and new policies aimed at marketing to children and labeling.
  • Only 31% of products met the independent health standard (a health star rating of 3.5 stars or more ). This equates to 11,797 of the 38,176 distinct products sold by the 25 companies globally
    • Just five companies were found to have half or more of their products meet the healthy threshold of 3.5 stars
    • Nine companies improved the average HSR of their products between 2018 and 2021.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release

Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye